Oral SERDs in Development for ER+/HER2- Metastatic Breast Cancer

A breast medical oncologist reviews oral SERDs currently in development for the treatment of patients with ER+/HER2 metastatic breast cancer, highlighting camizestrant, imlunestrant, and giredestrant.

EP: 1.Evolution of Endocrine Therapies in ER+/HER2– Metastatic Breast Cancer

EP: 2.Efficacy and Safety of Oral SERDs and Other Endocrine Therapies in ER+/HER2- Metastatic Breast Cancer

EP: 3.Elacestrant Usage in ER+/HER2- Metastatic Breast Cancer: Clinical Guidelines and Patient Profiles

EP: 4.ESR1 Mutation Testing and Precision Medicine in Patients With ER+/HER2- Metastatic Breast Cancer

EP: 5.Elacestrant in Later-Line Treatment of ER+/HER2– Metastatic Breast Cancer

EP: 6.Elacestrant: Treatment Considerations, Including Dosing and Compliance

EP: 7.Elacestrant: Adverse Effects and Their Management, and Impact of Treatment on Quality of Life

EP: 8.Emerging Agents and Clinical Perspectives in ER+/HER2- Metastatic Breast Cancer

EP: 9.Overview of ESR1 Mutations in ER+/HER2- Metastatic Breast Cancer

EP: 10.Best Practices for ESR1 Mutation Testing in Patients With Breast Cancer

EP: 11.The Role of Oral SERDs in ER+/HER2- Metastatic Breast Cancer

Now Viewing

EP: 12.Oral SERDs in Development for ER+/HER2- Metastatic Breast Cancer

EP: 13.Research Landscape: Endocrine Therapies for ER+/HER2- Metastatic Breast Cancer

Related Videos

Related Content

Advertisement

August 14th 2025

Temporal Shift in Prevalence of Heart Failure Diagnoses and Comorbidities Within 2 US Integrated Health Systems

Mario Enrico Canonico, MD, PhD Judith Hsia, MD Shih-Ting Chiu, PhD Pu-Kai Tseng James O. Mudd, MD Joshua D. Remick, MD Bansi Patel, MS Ya-Hsiu Chuang, PhD Ty J. Gluckman, MD, MHA, FACC, FAHA, FASPC Marc P. Bonaca, MD, MPH

August 14th 2025

High Costs, Coverage Variability Limit Access to Incretin Mimetics for Weight Management

Brooke McCormick Stephen Lott, PharmD, MS Jonathan Gabison, MD, DABOM

August 14th 2025

Assessment of Variation in Ambulatory Cardiac Monitoring Among Commercially Insured Patients

Pierantonio Russo, MD Henriette Coetzer, MD Erik M. Hendrickson, PhD Kenneth Boyle, DC Brent Wright, DrPH

August 14th 2025

Five Years Later: Ongoing COVID-19 Challenges, Next Steps

Brooke McCormick

August 14th 2025

Care Quality Metrics in Medicare During COVID-19 Pandemic

Jeanette Thornton, MPA Mark Hamelburg, JD Lynn Nonnemaker, PhD Sherzod Abdukadirov, PhD German Veselovskiy, MPP Sari Siegel, PhD

August 14th 2025

Switching Biologics in Psoriasis Boosts Effectiveness but Raises Infection Risk

Pearl Steinzor

Related Content

Advertisement

August 14th 2025

Temporal Shift in Prevalence of Heart Failure Diagnoses and Comorbidities Within 2 US Integrated Health Systems

Mario Enrico Canonico, MD, PhD Judith Hsia, MD Shih-Ting Chiu, PhD Pu-Kai Tseng James O. Mudd, MD Joshua D. Remick, MD Bansi Patel, MS Ya-Hsiu Chuang, PhD Ty J. Gluckman, MD, MHA, FACC, FAHA, FASPC Marc P. Bonaca, MD, MPH

August 14th 2025

High Costs, Coverage Variability Limit Access to Incretin Mimetics for Weight Management

Brooke McCormick Stephen Lott, PharmD, MS Jonathan Gabison, MD, DABOM

August 14th 2025

Assessment of Variation in Ambulatory Cardiac Monitoring Among Commercially Insured Patients

Pierantonio Russo, MD Henriette Coetzer, MD Erik M. Hendrickson, PhD Kenneth Boyle, DC Brent Wright, DrPH

August 14th 2025

Five Years Later: Ongoing COVID-19 Challenges, Next Steps

Brooke McCormick

August 14th 2025

Care Quality Metrics in Medicare During COVID-19 Pandemic

Jeanette Thornton, MPA Mark Hamelburg, JD Lynn Nonnemaker, PhD Sherzod Abdukadirov, PhD German Veselovskiy, MPP Sari Siegel, PhD

August 14th 2025

Switching Biologics in Psoriasis Boosts Effectiveness but Raises Infection Risk

Pearl Steinzor